MedPath

The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males

Not Applicable
Conditions
Healthy
Interventions
Dietary Supplement: High-flavanol milk choocolate
Dietary Supplement: Low-flavanol milk chocolate
Registration Number
NCT02789761
Lead Sponsor
University of Reading
Brief Summary

A randomised, placebo-controlled, parallel human dietary intervention trial conducted in 33 healthy males to investigate the vascular and cognitive effects of bi-daily consumption of high-flavanol (epicatechin-rich) milk chocolate over a 2-week intervention period. Subjects visited the Hugh Sinclair Unit of Human Nutrition on 3 separate occasions; at the beginning, end and post-intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
34
Inclusion Criteria

Not provided

Exclusion Criteria
  • Haemoglobin (anaemia marker) < 125 g/l
  • Gamma GT (liver enzymes) > 80 IU/l
  • Total Cholesterol > 6.5 mmol/l
  • Suffered a myocardial infarction or stroke in the last 12 months
  • Suffers from any cardiovascular or metabolic disorders
  • Suffers from any blood-clotting disorder, and/or takes supporting medication
  • Any dietary restrictions or on a weight reducing diet
  • On any lipid-modifying or blood pressure lowering medication
  • Consuming any specific vitamin/ herbal supplements or fish oils

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High-flavanol milk chocolateHigh-flavanol milk choocolateBi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
Low-flavanol milk chocolateLow-flavanol milk chocolateBi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately \<1 mg of (-)-epicatechin for 2-weeks (14 days)
Primary Outcome Measures
NameTimeMethod
Flow-mediated Dilation (FMD)Change from baseline at 14 days

Ultrasound-based assessment of brachial artery reactivity following induced reactive hyperemia

Secondary Outcome Measures
NameTimeMethod
Blood pressure (BP)Change from baseline at 14 days

Acute assessment of systolic and diastolic BP (3 repeats)

Plasma Nitrite & Nitrate analysisChange from baseline at 14 days

HPLC-based system with inbuilt colorimetric Griess reaction assay for the assessment of Nitrite \& Nitrate in plasma

Endothelial progenitor cells and MicroparticlesChange from baseline at 14 days

Flow cytometric analysis using whole blood

Serum analysis of insulinChange from baseline at 14 days

ELIZA kits for determination of insulin concentration in serum

Plasma flavanol metabolite analysisChange from baseline at 14 days

HPLC-MS assessment of metabolite profile and content of plasma

Serum analysis of cardivascular-related blood marker(s) concentrationChange from baseline at 14 days

ILAB assessment of serum content of glucose, Triglycerides, total cholesterol, HDL-cholesterol, C-reactive protein and Non-esterified fatty acids

Executive FunctionChange from baseline at 14 days

Assessed by cognitive test battery

© Copyright 2025. All Rights Reserved by MedPath